AstraZeneca Archives

News and Trends 29 Sep 2016

Boehringer buys a €210M ticket to Virus-based Immuno-Oncology

Boehringer Ingelheim has signed a deal with ViraTherapeutics, an Austrian start-up that focuses on the development of oncolytic virus therapies. If everything goes well, the big Pharma could acquire the Biotech start-up after completion of Phase I trials. Boehringer Ingelheim has its eye on ViraTherapeutics’ oncolytic virus platform. The young Biotech’s technology establishes a novel treatment approach that […]

September 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 21 Sep 2016

A new player has entered the Game: €29M for DDR Cancer Therapy

Artios Pharma, launched in May this year, just received €29M (£25M) in Series A to develop cancer treatments. Its technology targets the DNA-Damage Response (DDR) and could overcome one of the main challenges of cancer therapy. Top-notch investors from Europe and the US have eagerly thrown cash at Artios Pharma in their search for new cancer treatments. […]

September 21, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

astrazeneca moderna mrna biotech investing

News and Trends 12 Aug 2016

mRNA Money-magnet increases its Pile of Cash to over €1.3Bn

Moderna is taking Biotech investing to new heights, as it has now increased total fundraising&partnership cash to an unbelievable €1.34Bn ($1.5Bn). It can thank AstraZeneca, which is now adding €126M more to its investment. Amid dropping revenues and pipeline cuts, AstraZeneca remains steadily focused on innovation and Biotech. After all, this was the strategy CEO Pascal […]

August 12, 2016 - 2 minutesmins - By Denise Neves Gameiro

mrna astrazeneca cardiometabolic diseases moderna

News and Trends 27 Jul 2016

AstraZeneca plans Phase I trial with mRNA therapy for Cardiovascular Disease

The collaboration between AstraZeneca and the money-magnet Moderna is giving its first steps. AstraZeneca is filing for authorization of a German Phase I trial, to assess an mRNA therapy for cardiometabolic diseases. Therapies using mRNA have a lot of potential as biologics. Leading Biotechs in the field include CureVac (interview with its CCO here) and […]

July 27, 2016 - 3 minutesmins - By Denise Neves Gameiro

leo pharma astrazeneca dermatology biologics

News and Trends 4 Jul 2016

Danish Pharma enters in the Biologics arena with Antibody Buy-out

Leo Pharma is acquiring rights to two of AstraZeneca‘s candidates. The targeted indications are atopic dermatitis and psoriasis – autoimmune conditions getting more and more attention. Based near Copenhagen (Denmark), Leo Pharma specializes in dermatological therapies – particularly topical treatments. The company is not shy about its acquisitions, having entered a €675M deal to buy Japanese […]

July 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

astrazeneca asthma copd epigenetic targets

News and Trends 21 Jun 2016

UK Partnership is looking for new Epigenetic targets in Respiratory Disease

AstraZeneca and MRC Technology are launching an initiative to find new epigenetic targets in respiratory disease. By picking promising academic research, the two parties expect to lock in new drugs for diseases like asthma. After partnering up with genomics elite for a new biobank, AstraZeneca is again preparing to tap into collaborations with academia. This […]

June 21, 2016 - 2 minutesmins - By Denise Neves Gameiro

astrazeneca centre genomics research hli wellcome fimm

News and Trends 25 Apr 2016

AstraZeneca partners up with Genomics Elite for new Biobank

AstraZeneca has announced it will create a new Centre for Genomics Research in Cambridge (UK) – joining the Wellcome Sanger, a Craig Venter Biotech and a Finnish specialist Institute to do so. AstraZeneca is betting on genomics to transform drug discovery and support its R&D pipeline. The idea is to create a ‘biobank‘ with genome analysis, integrated with data from […]

April 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

lipigon astrazeneca lipoprotein lipase lpl cardiovascular

News and Trends 11 Apr 2016

Swedish Startup close to the North Pole signs 100 million deal with AstraZeneca

Lipigon Pharmaceuticals will now count with AstraZeneca to push the development of its Lipoprotein Lipase strategies. This could produce novel drugs to tackle metabolic and cardiovascular disease, still the leading cause of death worldwide. Lipigon is a spinout of Umeå University, developing new drugs based on research of lipid metabolism. Umeå may have one of the most remote universities […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 4 Apr 2016

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016

BIO-Europe Spring 2016 is starting off right away with the plenary opening session. The conference was about partnering, trends and opinion from both Biotechs and Pharma… This was the list of pretty impressive speakers: How are Big Pharma positioning themselves in 2016? J&J clearly wants to open up more to the outside of the organisation, […]

April 4, 2016 - 5 minutesmins - By Philip Hemme

cambridge gsk ucl imperial apollo jj astrazeneca

News and Trends 27 Jan 2016

New UK Joint Venture Bridges Gap between Top Universities and Big Pharmas

AstraZeneca, GlaxoSmithKline, Johnson & Johnson and the 3 world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces to found the ‘Apollo’ Bridge. This pioneering new joint venture, the Apollo Therapeutics Fund, will support the translation of ground-breaking academic science from within these universities into innovative new medicines for […]

January 27, 2016 - 3 minutesmins - By Dani Bancroft

innate pharma immunooncology biotech cancer orega sanofi

News and Trends 11 Jan 2016

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Marseille’s Innate Pharma is building an Immuno-Oncology Monopoly, deal by deal. Selling to the French Pharma Giant, Sanofi, this 112 employee biotech has used their Sanofi-income to buy up Lyon-based Orega Biotech‘s checkpoint inhibitor program. Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

Universal cancer diagnostic test illumina bill gates grail guardant health ngs

News and Trends 11 Jan 2016

How about the $100M Holy ‘GRAIL’ in Cancer Diagnostics? A Universal Test Start-up Faces German Competition

Illumina, the €22Bn Market cap NGS specialist, and Bill Gates pooled a $100M to fund the startup, ‘Grail’, which will be used to find a universal cancer detection test for Doctors. The startup will be based in San Francisco (US) with additional financial backing to include Bill Gates amongst others. The tests in question are […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us